Background: Polyneuropathy with IgM monoclonal gammopathy can be a disabling disorder necessitating treatment.
Methods: In a prospective open label trial, 17 patients with disabling IgM MGUS polyneuropathy were treated with rituximab, a chimeric anti-CD-20 monoclonal antibody.
Results: Rituximab induced an improvement of ⩾1 point on the Overall Disability Sum Score in 2/17 patients, an improvement of ⩾5% of the distal MRC sum score in 4/17 and the sensory sum score in 9/17 patients. Bone marrow investigations showed CD 20 B cell depletion in all patients. There were no serious adverse events. Compared with treatment with intermittent cyclophosphamide with prednisone or treatment with fludarabine, it shows a comparable response percentages but fewer side effects. The presence of anti-MAG and a disease duration shorter than 10 years may predict treatment response.
Conclusion: Rituximab is a candidate for treatment of IgM MGUS polyneuropathy and should be further investigated in a double-blind randomised trial.
Statistics from Altmetric.com
Competing interests None.
Ethics approval Ethics approval was provided by the medical ethics committee of the University Medical Centre, Utrecht.
Patient consent Obtained.
Statistical analysis was performed by JMFN.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.